Scilex Holding (SCLXW) Liabilities and Shareholders Equity (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Liabilities and Shareholders Equity of $293.6 million in Q1 2026, down 19.55% quarter-over-quarter from $365.0 million in Q4 2025, and up 271.8% on a YoY basis from $79.0 million in Q1 2025.
Scilex Holding (SCLXW) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Scilex Holding's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $293.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
- Liabilities and Shareholders Equity was $293.6 million for Q1 2026 at Scilex Holding, down from $365.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $365.0 million in Q4 2025 to a low of $79.0 million in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $138.4 million across 5 years, with a median of $101.3 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity tumbled 38.96% in 2023, then soared 292.65% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $86.5 million in 2022, then grew by 17.08% to $101.3 million in 2023, then declined by 8.25% to $93.0 million in 2024, then jumped by 292.65% to $365.0 million in 2025, then decreased by 19.55% to $293.6 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $293.6 million (Q1 2026), $365.0 million (Q4 2025), and $275.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 293.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.64 Mn |
| Dec 31, 2025 | 364.98 Mn |
| Sep 30, 2025 | 275.88 Mn |
| Jun 30, 2025 | 83.76 Mn |
| Mar 31, 2025 | 78.98 Mn |
| Dec 31, 2024 | 92.95 Mn |
| Sep 30, 2024 | 100.43 Mn |
| Jun 30, 2024 | 104.54 Mn |
| Mar 31, 2024 | 91.24 Mn |
| Dec 31, 2023 | 101.31 Mn |
| Sep 30, 2023 | 80.53 Mn |
| Jun 30, 2023 | 126.46 Mn |
| Mar 31, 2023 | 86.05 Mn |
| Dec 31, 2022 | 86.53 Mn |
| Sep 30, 2022 | 101.46 Mn |
| Jun 30, 2022 | 142.30 Mn |
| Mar 31, 2022 | 140.97 Mn |
| Dec 31, 2021 | 77.93 Mn |
| Sep 30, 2021 | 139.64 Mn |
| Jun 30, 2021 | 139.90 Mn |